Research Analysts Issue Forecasts for ChromaDex Q4 Earnings

ChromaDex Co. (NASDAQ:CDXC - Free Report) - Stock analysts at Roth Capital decreased their Q4 2024 earnings per share (EPS) estimates for ChromaDex in a research note issued on Tuesday, November 5th. Roth Capital analyst S. Mcgowan now expects that the company will earn $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for ChromaDex's current full-year earnings is $0.02 per share. Roth Capital also issued estimates for ChromaDex's FY2025 earnings at $0.05 EPS and Q3 2026 earnings at $0.05 EPS.

ChromaDex (NASDAQ:CDXC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the previous year, the company earned ($0.01) EPS.

Several other brokerages also recently commented on CDXC. HC Wainwright boosted their target price on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday. Roth Mkm lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday.

ChromaDex Stock Down 3.1 %

NASDAQ:CDXC traded down $0.22 on Thursday, reaching $6.77. The stock had a trading volume of 991,149 shares, compared to its average volume of 508,773. The company has a market capitalization of $517.09 million, a P/E ratio of 677.68 and a beta of 1.88. ChromaDex has a 1-year low of $1.32 and a 1-year high of $7.08. The stock has a fifty day moving average price of $3.77 and a 200-day moving average price of $3.31.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently made changes to their positions in the company. OneDigital Investment Advisors LLC increased its position in ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock worth $217,000 after purchasing an additional 3,097 shares during the period. Miracle Mile Advisors LLC acquired a new stake in shares of ChromaDex during the 2nd quarter worth approximately $27,000. The Manufacturers Life Insurance Company bought a new stake in shares of ChromaDex during the second quarter worth approximately $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex in the second quarter valued at approximately $32,000. Finally, Lazard Asset Management LLC bought a new position in ChromaDex in the first quarter valued at approximately $43,000. Institutional investors own 15.41% of the company's stock.

Insider Buying and Selling at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of the company's stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 9.64% of the company's stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.